GlaxoSmithKline Pharmaceuticals Limited Depreciation And Amortization for the year ending March 31, 2025: USD 7.82 M

GlaxoSmithKline Pharmaceuticals Limited Depreciation And Amortization is USD 7.82 M for the year ending March 31, 2025, a -6.44% change year over year. Depreciation and amortization are expense that reduces the value of tangible and intangible assets over their useful lives for tax and reporting purposes.
  • GlaxoSmithKline Pharmaceuticals Limited Depreciation And Amortization for the year ending March 31, 2024 was USD 8.35 M, a 4.39% change year over year.
  • GlaxoSmithKline Pharmaceuticals Limited Depreciation And Amortization for the year ending March 31, 2023 was USD 8.00 M, a -10.89% change year over year.
  • GlaxoSmithKline Pharmaceuticals Limited Depreciation And Amortization for the year ending March 31, 2022 was USD 8.98 M, a -17.06% change year over year.
  • GlaxoSmithKline Pharmaceuticals Limited Depreciation And Amortization for the year ending March 31, 2021 was USD 10.83 M, a -1.31% change year over year.
Key Data
Date Depreciation And Amortization Dividends Paid Common Stock Issued Common Stock Repurchased